765 related articles for article (PubMed ID: 19190809)
1. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
2. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
3. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Sethi S; Fervenza FC
Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
[TBL] [Abstract][Full Text] [Related]
4. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
5. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.
Pickering MC; Cook HT; Warren J; Bygrave AE; Moss J; Walport MJ; Botto M
Nat Genet; 2002 Aug; 31(4):424-8. PubMed ID: 12091909
[TBL] [Abstract][Full Text] [Related]
6. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
7. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
10. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
[TBL] [Abstract][Full Text] [Related]
11. Management of membranoproliferative glomerulonephritis type II with plasmapheresis.
Kurtz KA; Schlueter AJ
J Clin Apher; 2002; 17(3):135-7. PubMed ID: 12378549
[TBL] [Abstract][Full Text] [Related]
12. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.
Appel GB; Cook HT; Hageman G; Jennette JC; Kashgarian M; Kirschfink M; Lambris JD; Lanning L; Lutz HU; Meri S; Rose NR; Salant DJ; Sethi S; Smith RJ; Smoyer W; Tully HF; Tully SP; Walker P; Welsh M; Würzner R; Zipfel PF
J Am Soc Nephrol; 2005 May; 16(5):1392-403. PubMed ID: 15800116
[TBL] [Abstract][Full Text] [Related]
13. [Familial membranoproliferative glomerulonephritis].
Bogdanović RM; Dimitrjević JZ; Nikolić VN; Ognjanović MV; Rodić BD; Slavković BV
Srp Arh Celok Lek; 1999; 127(5-6):163-71. PubMed ID: 10500423
[TBL] [Abstract][Full Text] [Related]
14. [An approach to research on nephritic factor and membranoproliferative glomerulonephritis].
Ohi H
Nihon Jinzo Gakkai Shi; 2012; 54(7):1006-15. PubMed ID: 23234212
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor B autoantibody in dense deposit disease.
Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
[TBL] [Abstract][Full Text] [Related]
17. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
18. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.
Servais A; Noël LH; Dragon-Durey MA; Gübler MC; Rémy P; Buob D; Cordonnier C; Makdassi R; Jaber W; Boulanger E; Lesavre P; Frémeaux-Bacchi V
Hum Pathol; 2011 Sep; 42(9):1305-11. PubMed ID: 21396679
[TBL] [Abstract][Full Text] [Related]
20. Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis.
Montes T; Goicoechea de Jorge E; Ramos R; Gomà M; Pujol O; Sánchez-Corral P; Rodríguez de Córdoba S
Mol Immunol; 2008 May; 45(10):2897-904. PubMed ID: 18336910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
